PDCD1 and non-small cell lung carcinoma: Similarly, in a recent meta-analysis of comparing the efficacy and safety of PD1/PDL1 for advanced NSCLC patients, durvalumab was considered to be the most toxic agent among several ICI regimens (durvalumab, nivolumab, atezolizumab, and pembrolizumab) in terms of SAEs or respiratory and thoracic disorders in the second-line or further-line settings [42].